The medicines business | A question to investigate
A forecast needs a reason to be believed
Demand is not the same as the orders arriving today. A sudden increase might reflect genuine consumption, stock building, a competitor’s interruption or a change in how a customer buys. Treating those explanations as interchangeable can distort replenishment decisions. NEUVIOR is interested in helping medicines businesses compare the explanations behind a demand signal and identify what evidence would justify a change in action.
In the conversation.
NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.
Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.
The question behind the movement
A planning team needs to know whether a change is temporary, persistent or not yet interpretable. Commercial teams may favour a growth explanation; operations may favour caution; customers may be protecting continuity. The useful discussion begins by separating observed activity from its possible causes. It then asks which decision is actually open: changing procurement, adjusting production, investigating a customer pattern or waiting for better information within an agreed risk boundary.
Public data offers context, not a live order book
NHSBSA’s Prescription Cost Analysis describes community dispensing in England (NHSBSA, n.d.). DHSC’s supply-disruption statistics are derived from reported notifications (DHSC, n.d.). These sources can inform context but cannot independently reveal a particular manufacturer’s next month of orders. A proposed review would keep their coverage, dates and units visible. It would not combine them into an apparently real-time picture of private stock positions or assume a reporting count measures patient demand.
Separate consumption, ordering and stock
A useful comparison may require three clocks: when a prescription item was dispensed, when a customer placed an order and when stock became available. Aggregating them by calendar month can hide the sequence that explains a spike. Returns, cancelled orders and changes in pack size also matter. Before discussing predictive models, the team should agree what each quantity means and which transformations are legitimate for the commercial decision under consideration.
The decision threshold should be visible
A useful deliverable would identify what new evidence would justify changing the plan. That might be confirmation of a customer pattern, reconciliation of cancelled orders or a sustained movement across comparable periods. The team could then distinguish a reason to investigate from a reason to commit additional stock, with the threshold agreed before the next signal arrives.
A public decision brief | An illustrative example
Open the question.
Inspect the reasoning.
Choose a business question, then look beneath its claim. See what a public source supports, what depends on the local setting and what a useful next step could be.
A medicines or implementation team considering an AI-supported evidence review.
Would a quicker review make the decision better?
The interesting question is the complete piece of work: finding relevant material, checking it, correcting the draft and reaching an accountable decision.
A proposition to investigate
Less preparation. The same ability to challenge.
An evidence-review approach could be useful if it reduces avoidable preparation while preserving source access, relevant qualifications and professional checking. That is the proposed value to test. No time reduction, accuracy improvement or customer result is asserted in this example.
The proposition is constructed for this public brief. It is not a published finding about PHARMORIS.
What the next brief would contain
A decision someone
can commission.
- The decision
- Whether one defined review task merits an agreed evaluation.
- The comparator
- The team's existing complete review process, including checking and corrections.
- The evidence
- Representative cases, source records, reviewer decisions, complete-task effort and exceptions.
- Stop or redesign
- Stop or redesign if source checking weakens, errors are unacceptable or the complete task offers insufficient value.
Constructed public example | Not PHARMORIS-generated software output or a measured customer result.
Keep this example briefA narrow proposed study
We would begin with one product family and a defined historical decision window. Inputs could include permitted aggregate orders, fulfilled quantities, returns, stock positions and relevant dated public context. The comparator would be the organisation’s existing forecast and planning judgement recorded at the time. A proposed PHARMORIS evaluation would assess alternative explanations and scenario ranges using only information that was available before the historical decision, avoiding hindsight disguised as intelligence.
Judge decisions as well as errors
Forecast error alone may not capture business value. Being slightly wrong when stock is plentiful differs from being wrong during a constrained replenishment period. Candidate outcomes therefore include calibration of uncertainty ranges, evidence supporting a change in plan, unnecessary plan reversals and the work required to investigate exceptions. Any cost or service consequence should use agreed local assumptions and remain distinct from an observed commercial outcome.
Stop when the signal cannot carry the claim
The study should pause if orders cannot be distinguished from shipments, if structural product changes invalidate comparison, or if the available history contains too few comparable events. It should stop if users want a confident demand number where the evidence only supports several possibilities. A useful result can be a better question or an improved data definition. It need not produce a model, an automation programme or a claim of superior forecasting.
A conversation for planning and commercial leaders
Bring an example where a demand movement led to a difficult decision and explain the consequences of changing too early or too late. We can discuss what information was available, what was missing and whether a bounded comparison would be worthwhile. The incentive is a more defensible planning conversation across functions, with a clear route from an observed signal to a proportionate investigation before the business commits stock, capacity or capital.
Sources and scope
NHSBSA | Prescription Cost Analysis England | DHSC | Medicine supply disruption statistics to June 2026
NHSBSA (n.d.) Prescription Cost Analysis England. Available at: https://www.nhsbsa.nhs.uk/statistical-collections/prescription-cost-analysis-england (Accessed: 14 October 2026).
DHSC (n.d.) Medicine supply disruption statistics to June 2026. Available at: https://www.gov.uk/government/statistics/medicine-supply-disruption-statistics-uk-data-to-june-2026/medicine-supply-disruption-statistics-uk-data-to-june-2026 (Accessed: 14 October 2026).
Another useful angle.
- Before a product leaves the portfolio
A proposed discontinuation decision review connecting commercial constraints, supply implications, reporting and alternatives.
- Which supply exception deserves attention first?
Explore a proposed wholesale exception-review evaluation that compares effort, escalation and operational consequences.
- Before a shortage becomes everybody’s problem
A proposed readiness review for marketing authorisation holders connecting supply evidence, reporting ownership and action.